In today’s recent session, 0.47 million shares of the Travere Therapeutics Inc (NASDAQ:TVTX) have been traded, and its beta is 0.78. Most recently the company’s share price was $20.94, and it changed around -$0.07 or -0.33% from the last close, which brings the market valuation of the company to $1.86B. TVTX at last check was trading at a discount to its 52-week high of $25.29, offering almost -20.77% off that amount. The share price’s 52-week low was $5.12, which indicates that the recent value has risen by an impressive 75.55% since then. We note from Travere Therapeutics Inc’s average daily trading volume that its 10-day average is 1.61 million shares, with the 3-month average coming to 1.59 million.
Travere Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.13. If we narrow it down even further, the data shows that 0 out of 16 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 2 recommended TVTX as a Hold, whereas 11 deemed it a Buy, and 0 rated it as Underweight. Travere Therapeutics Inc is expected to report earnings per share of -0.36 for the current quarter.
Travere Therapeutics Inc (NASDAQ:TVTX) trade information
Instantly TVTX has been showing red trend so far today with a performance of -0.33% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 21.35 on recent trading dayincreased the stock’s daily price by 1.92%. The company’s shares are currently up 20.21% year-to-date, but still up 1.16% over the last five days. On the other hand, Travere Therapeutics Inc (NASDAQ:TVTX) is 1.40% up in the 30-day period. We can see from the shorts that 11.19 million shares have been sold at a short interest cover period of 6.65 day(s).
The consensus price target as assigned by Wall Street analysts is $21.5, which translates to bulls needing to increase their stock price by 2.6% from its current value. Analyst projections state that TVTX is forecast to be at a low of $18 and a high of $33.
Travere Therapeutics Inc (TVTX) estimates and forecasts
The year-over-year growth rate is expected to be 68.00%, up from the previous year.
Consensus estimates provided by 12 financial analysts predict the company will bring in an average of 77.53M in revenue for the current quarter. 12 analysts expect Travere Therapeutics Inc to make 89.56M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 41.37M and 54.12M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 87.38%. Forecasts for the next quarter put sales growth at 65.50%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -3.34%.
Travere Therapeutics Inc (NASDAQ:TVTX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.63% of Travere Therapeutics Inc shares, and 109.23% of them are in the hands of institutional investors. The stock currently has a share float of 109.92%. Travere Therapeutics Inc stock is held by 273.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-06-30, it held 9.8642% of the shares, which is about 7.64 million shares worth $62.84 million.
ARMISTICE CAPITAL, LLC, with 9.6774% or 7.5 million shares worth $61.65 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Macquarie Small Cap Core Fund and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Nov 30, 2024. The former held 3.45 shares worth $71.28 million, making up 3.89% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 2.71 shares worth around $55.99 million, which represents about 3.06% of the total shares outstanding.
